Nonresponder Considerations for Romosozumab Treatment

[1]  E. Lewiecki,et al.  Romosozumab and antiresorptive treatment: the importance of treatment sequence , 2022, Osteoporosis International.

[2]  Y. Sakai,et al.  Bisphosphonate treatment is associated with decreased mortality rates in patients after osteoporotic vertebral fracture , 2022, Osteoporosis International.

[3]  K. Insogna,et al.  Update on Osteoporosis Screening and Management. , 2021, The Medical clinics of North America.

[4]  K. Ebina,et al.  Effects of prior osteoporosis treatment on 12-month treatment response of romosozumab in patients with postmenopausal osteoporosis. , 2021, Joint Bone Spine.

[5]  M. Saito,et al.  Real-world effects and adverse events of romosozumab in Japanese osteoporotic patients: A prospective cohort study , 2021, Bone reports.

[6]  N. Iwasaki,et al.  Effects after starting or switching from bisphosphonate to romosozumab or denosumab in Japanese postmenopausal patients , 2021, Journal of Bone and Mineral Metabolism.

[7]  K. Okazaki,et al.  Early clinical effects, safety, and predictors of the effects of romosozumab treatment in osteoporosis patients: one-year study , 2021, Osteoporosis International.

[8]  B. Crawford,et al.  Family caregiver burden of patients with osteoporotic fracture in Japan , 2021, Journal of Bone and Mineral Metabolism.

[9]  K. Okazaki,et al.  Early clinical effects, safety, and appropriate selection of bone markers in romosozumab treatment for osteoporosis patients: a 6-month study , 2020, Osteoporosis International.

[10]  A. Grauer,et al.  Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to romosozumab or teriparatide: a post hoc analysis of the STRUCTURE trial , 2019, Journal of Bone and Mineral Metabolism.

[11]  C. Christiansen,et al.  Bone mineral density response rates are greater in patients treated with abaloparatide compared with those treated with placebo or teriparatide: Results from the ACTIVE phase 3 trial. , 2019, Bone.

[12]  A. Grauer,et al.  FRAME Study: The Foundation Effect of Building Bone With 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab , 2018, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[13]  A. Grauer,et al.  Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: A phase 2 study. , 2017, Bone.

[14]  R. Eastell,et al.  Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability , 2017, Osteoporosis International.

[15]  Michael F. Holick,et al.  The vitamin D deficiency pandemic: Approaches for diagnosis, treatment and prevention , 2017, Reviews in Endocrine and Metabolic Disorders.

[16]  A. Sudo,et al.  A retrospective analysis of nonresponse to daily teriparatide treatment , 2016, Osteoporosis International.

[17]  J. Souberbielle,et al.  Inter-method variability in bone alkaline phosphatase measurement: clinical impact on the management of dialysis patients. , 2014, Clinical biochemistry.

[18]  H. Ke,et al.  Tissue‐Level Mechanisms Responsible for the Increase in Bone Formation and Bone Volume by Sclerostin Antibody , 2014, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[19]  Y. Kanda,et al.  Investigation of the freely available easy-to-use software ‘EZR' for medical statistics , 2012, Bone Marrow Transplantation.

[20]  S. Greenspan,et al.  Application of a New Serum Assay for Type I Collagen Cross-Linked N-Telopeptides: Assessment of Diurnal Changes in Bone Turnover With and Without Alendronate Treatment , 1998, Calcified Tissue International.

[21]  J. Krege,et al.  PINP as an aid for monitoring patients treated with teriparatide. , 2011, Bone.

[22]  L. Lix,et al.  Mortality rates after incident non-traumatic fractures in older men and women , 2011, Osteoporosis International.

[23]  R. Cumming,et al.  Oral bisphosphonates are associated with reduced mortality in frail older people: a prospective five-year study , 2011, Osteoporosis International.

[24]  H. Macdonald,et al.  Changes in trabecular and cortical bone microarchitecture at peripheral sites associated with 18 months of teriparatide therapy in postmenopausal women with osteoporosis , 2010, Osteoporosis International.

[25]  M. Kurajoh,et al.  Utility of serum tartrate‐resistant acid phosphatase (TRACP5b) as a bone resorption marker in patients with chronic kidney disease: independence from renal dysfunction , 2008, Clinical endocrinology.

[26]  P. Garnero,et al.  Evaluation of a fully automated serum assay for total N-terminal propeptide of type I collagen in postmenopausal osteoporosis. , 2008, Clinical chemistry.

[27]  R. Marcus,et al.  Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis. , 2006, Bone.

[28]  O. Johnell,et al.  Mortality after osteoporotic fractures , 2004, Osteoporosis International.

[29]  Minako Y. Lee,et al.  Acid phosphatases as markers of bone metabolism. , 2002, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[30]  M Dioszegi,et al.  Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). , 2001, Human molecular genetics.

[31]  P. Tothill,et al.  Comparisons between three dual-energy X-ray absorptiometers used for measuring spine and femur. , 1995, The British journal of radiology.